How will yervoy's patent expiration impact its cost?

How does Yervoy's patent expiration affect its price?

Yervoy (ipilimumab) is a checkpoint inhibitor used to treat melanoma and other cancers. Bristol-Myers Squibb holds the primary composition-of-matter patent that covers the antibody itself. That patent expires in 2025.

How does this timing compare with current pricing?

Yervoy costs roughly $185,000 for a full course of treatment. This figure is set by the brand company and includes recent price hikes that tracked inflation and market conditions. The company still retains marketing exclusivity through 2025.

What happens when biosimilars arrive?

Biosimilars typically enter the market once patents expire and regulatory approval is granted. In the U.S., the Biologics Price Competition and Innovation Act gives the innovator twelve years of market exclusivity. That window ends in 2025 for Yervoy. Biosimilar versions are already in development or under review by companies such as Amgen, Merck, and Samsung Bioepis.

What price drop can patients expect?

Historical data on biosimilar launches show average price reductions of 30-40 percent relative to the brand price. In the European Union, some oncology biologics have seen cuts of 50 percent or more. Price discounts often increase as more entrants arrive, but the U.S. market is slower to adopt biosimilars because of interchangeability designations and physician prescribing habits.

Why are companies challenging this patent?

Several firms have filed inter partes review petitions against Yervoy-related patents. These challenges aim to clear invalidity obstacles before 2025, so they can launch biosimilars earlier. Success would accelerate availability and further depress prices.

When does exclusivity expire?

U.S. regulatory exclusivity ends in 2025 for the melanoma indication. Other indications may still be protected by method-of-use or formulation patents that extend beyond 2025.